Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Soligenix stock

SNGX
US8342233074
A2AS7Q

Price

3.50
Today +/-
+0.03
Today %
+0.86 %
P

Soligenix stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Soligenix stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Soligenix stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Soligenix stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Soligenix's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Soligenix Stock Price History

DateSoligenix Price
11/8/20243.50 undefined
11/7/20243.47 undefined
11/6/20243.50 undefined
11/5/20243.62 undefined
11/4/20243.65 undefined
11/1/20243.86 undefined
10/31/20243.67 undefined
10/30/20243.73 undefined
10/29/20243.80 undefined
10/28/20243.96 undefined
10/25/20243.88 undefined
10/24/20243.72 undefined
10/23/20243.58 undefined
10/22/20243.75 undefined
10/21/20243.59 undefined
10/18/20243.87 undefined
10/17/20243.63 undefined
10/16/20243.53 undefined
10/15/20243.60 undefined
10/14/20243.52 undefined
10/11/20243.90 undefined

Soligenix Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Soligenix, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Soligenix from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Soligenix’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Soligenix. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Soligenix’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Soligenix’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Soligenix’s growth potential.

Soligenix Revenue, EBIT and net profit per share

DateSoligenix RevenueSoligenix EBITSoligenix Net Income
2026e918,000 undefined-10.51 M undefined-11.47 M undefined
2025e918,000 undefined-8.85 M undefined-11.78 M undefined
2024e519,690 undefined-8.09 M undefined-13.94 M undefined
2023839,360 undefined-7.7 M undefined-6.14 M undefined
2022950,000 undefined-14.24 M undefined-13.8 M undefined
2021820,000 undefined-13.1 M undefined-12.55 M undefined
20202.36 M undefined-18.59 M undefined-17.69 M undefined
20194.63 M undefined-10.54 M undefined-9.36 M undefined
20185.24 M undefined-9.06 M undefined-8.9 M undefined
20175.43 M undefined-7.59 M undefined-7.15 M undefined
201610.45 M undefined-5.71 M undefined-3.25 M undefined
20158.77 M undefined-7.11 M undefined-7.83 M undefined
20147.04 M undefined-10.76 M undefined-6.71 M undefined
20133.22 M undefined-7.16 M undefined-10.06 M undefined
20123.14 M undefined-4.69 M undefined-4.16 M undefined
20117.66 M undefined-2.96 M undefined-2.38 M undefined
20101.95 M undefined-7.88 M undefined-7.39 M undefined
20092.82 M undefined-6.05 M undefined-6.03 M undefined
20082.31 M undefined-3.46 M undefined-3.42 M undefined
20071.26 M undefined-6.33 M undefined-6.16 M undefined
20062.31 M undefined-6.4 M undefined-8.16 M undefined
20053.08 M undefined-4.68 M undefined-4.72 M undefined
20041 M undefined-5.92 M undefined-6.38 M undefined

Soligenix Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
0000000000000000000132122173378105542000000
--------------------200.00-33.33-50.00100.00--50.00600.00-57.14-133.3314.2925.00-50.00--20.00-50.00------
--------------------33.33---50.00-71.43--14.2912.5020.0020.00-25.00-------
000000000000000000001000105001121010000000
000-1-1000-1-1-1-2-3-5-5-3-4-5-5-5-4-6-6-3-6-7-2-4-7-10-7-5-7-9-10-18-13-14-7-8-8-10
--------------------500.00-133.33-300.00-600.00-150.00-300.00-700.00-28.57-133.33-233.33-142.86-87.50-50.00-140.00-180.00-250.00-900.00------
000-1-1000-1-10-1-3-22-8-6-16-6-6-6-4-8-6-3-6-7-2-4-10-6-7-3-7-8-9-17-12-13-6-13-11-11
------------200.00633.33-63.64-25.00166.67-62.50---33.33100.00-25.00-50.00100.0016.67-71.43100.00150.00-40.0016.67-57.14133.3314.2912.5088.89-29.418.33-53.85116.67-15.38-
000000000000000000.010.010.010.020.020.030.030.060.070.070.070.10.140.170.230.410.881.291.832.682.870.48000
------------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Soligenix Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Soligenix is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                                       
0.430.3100.025.213.72.241.020.9115.7113.158.5412.859.944.154.122.330.820.122.221.487.697.4563.365.865.534.928.777.818.985.4218.6826.0413.368.45
0000000000000.130.0400.020.740.560.090.10.280.020.120.360.340.870.791.991.210.931.21.020.20.140.120.17
00000000000000000000002505800750000410044036010010023.9
00000000000000000000804000000000000000
0.040.030.010.0100.040.050.040.051.721.820.10.060.050.10.160.060.140.090.120.090.140.190.20.140.140.170.240.130.260.160.610.230.280.270.87
0.470.340.010.035.213.742.291.060.9617.4314.978.6413.0410.034.254.33.131.520.32.441.937.898.017.143.847.626.497.1510.119.4110.347.4919.4726.5613.859.51
1701701207020540370180909046045038037026060504030302020202010205050304020160250130360241.76
00000000004000000000000000000000000000
000000000000000000000000000000000000
0.020.040.060.120.170.110.130.190.20.290.370.180.250.641.321.91.881.81.071.321.421.461.241.080.860.630.410.190.130.070.050.020000
000000000000000000000000000000000000
0000000001.2500000000000000000000.020.080.10.170.170.070.05
0.190.210.180.190.190.650.50.370.291.631.230.630.631.011.581.961.931.841.11.351.441.481.261.10.870.650.460.240.160.130.150.280.420.30.430.29
0.660.550.190.225.44.392.791.431.2519.0616.29.2713.6711.045.836.265.063.361.43.793.379.379.278.244.718.276.957.3910.279.5410.497.7719.8926.8614.289.8
                                                                       
0.030.0600.010.010.010.010.010.020.0117.0518.3419.7221.2111.7412.690.040.050.070.10.120.190.010.010.010.020.020.030.010.010.020.020.030.0400.01
2.283.343.483.699.9310.110.0710.0711.7732.3233.4133.6640.3748.9861.3267.0183.2286.0591.55101.39104.18116.34123.09124.9125.82130.55138.87146.83157.51163.58172.44177.01196.95216.4217.06228.19
-1.75-2.88-3.73-4.14-4.71-5.72-7.07-8.26-10.22-13.46-35.26-44.29-49.09-63.72-68.69-73.98-79.85-84.57-92.73-98.9-102.32-108.35-115.74-118.12-122.28-132.34-139.05-146.88-150.12-157.27-166.17-175.53-193.21-205.77-219.56-225.7
00000-90-1000000-100-500000000000000000-50-20402022.24
000000000000000000000000000000000000
0.560.52-0.25-0.445.234.331.821.5718.8715.27.7110.996.474.325.723.411.53-1.112.591.988.187.366.793.55-1.77-0.16-0.027.46.326.291.453.7510.71-2.482.52
0.070.020.20.2700.090.080.060.130.630.811.442.652.90.570.211.671.532.110.851.020.841.671.31.121.5234.381.711.752.132.742.132.933.871.11
0.030.010.10.210.11000000.240.190.150.210.250.440.30.210.40.350.370.370.240.130.030.230.320.31.161.482.093.583.633.372.752.79
00000000000000000000000008.283.792.4300000000
001401800000000000000000000000029000000000
00000000000.080.110.120.170.380.360.120.11000000000000000.3209.92.25
0.10.030.440.660.110.090.080.060.130.631.131.742.923.281.21.012.091.852.511.21.391.211.911.431.1510.037.117.42.873.234.226.326.086.316.526.15
00000000000.310.280.20.050.35000000000000000009.959.8601.01
000000000000000000000000000000000000
00005000000000000000000000000000101200230111.86
00000.05000000.310.280.20.050.3500000000000000000.0110.079.860.231.12
0.10.030.440.660.160.090.080.060.130.631.442.023.123.331.551.012.091.852.511.21.391.211.911.431.1510.037.117.42.873.234.226.3316.1516.1616.757.27
0.660.550.190.225.394.393.081.881.719.516.649.7314.119.85.876.735.53.381.43.793.379.399.278.224.78.266.957.3810.279.5510.517.7819.926.8714.279.8
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Soligenix provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Soligenix's financial health and stability.

Assets

Soligenix's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Soligenix must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Soligenix after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Soligenix's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
198719881989199019911992199319941995null1996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0-1-1000-1-1-1-1-1-3-21-7-4-14-4-5-5-4-8-6-3-6-7-2-4-10-6-7-3-7-8-9-17-12-13-6
00000000000000000000000000000000000000
00000000000000000000000000000000000000
00000000000001-1000001-1000-102-11-2011000-3
0000000000001842100100210111025000005000
00000000000000000000000000000000000000
00000000000000000000000000000000000000
00-10000-1-1-1-1-2-3-1-3-3-6-4-4-4-4-6-2-4-5-1-2-4-2-5-4-6-7-7-11-11-12-8
00000000000000000000000000000000000000
000000000000-18-5130000000000000000000000
000000000000-18-5130000000000000000000000
00000000000000000000000000000000000000
00000000000000000000000000000000001000-7
10000600001171807004333821150062496841519011
1000060000117180700423382115006248584241903
--------------------------------------
00000000000000000000000000000000000000
1-10005-1-1-1-1014-3-750-50-1-102060-1-2200301-3137-12-4
-0.62-1.06-1.09-0.48-0.07-0.83-1.53-1.12-1.010-1.54-2.34-3.48-2.11-3.49-4.12-6.08-4.24-4.69-4.94-4.35-6.36-3.03-4.82-6.07-2.1-2.64-4.48-2.52-5.41-4.99-6.54-7.24-7.54-11.46-11.75-12.66-8.6
00000000000000000000000000000000000000

Soligenix stock margins

The Soligenix margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Soligenix. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Soligenix.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Soligenix's sales revenue. A higher gross margin percentage indicates that the Soligenix retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Soligenix's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Soligenix's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Soligenix's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Soligenix. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Soligenix's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Soligenix Margin History

Soligenix Gross marginSoligenix Profit marginSoligenix EBIT marginSoligenix Profit margin
2026e11.59 %-1,144.44 %-1,248.93 %
2025e11.59 %-963.61 %-1,283.13 %
2024e11.59 %-1,557.11 %-2,682.75 %
202311.59 %-917.12 %-731.6 %
202242.11 %-1,498.95 %-1,452.63 %
202112.2 %-1,597.56 %-1,530.49 %
202022.88 %-787.71 %-749.58 %
201922.89 %-227.65 %-202.16 %
201812.21 %-172.9 %-169.85 %
201720.63 %-139.78 %-131.68 %
201619.33 %-54.64 %-31.1 %
201521.55 %-81.07 %-89.28 %
201424.57 %-152.84 %-95.31 %
201321.12 %-222.36 %-312.42 %
201217.52 %-149.36 %-132.48 %
201172.45 %-38.64 %-31.07 %
201015.9 %-404.1 %-378.97 %
200947.16 %-214.54 %-213.83 %
200818.18 %-149.78 %-148.05 %
200725.4 %-502.38 %-488.89 %
200615.15 %-277.06 %-353.25 %
200532.79 %-151.95 %-153.25 %
20046 %-592 %-638 %

Soligenix Stock Sales Revenue, EBIT, Earnings per Share

The Soligenix earnings per share therefore indicates how much revenue Soligenix has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Soligenix earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Soligenix's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Soligenix’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Soligenix's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Soligenix Revenue, EBIT and net profit per share

DateSoligenix Sales per ShareSoligenix EBIT per shareSoligenix Earnings per Share
2026e0.4 undefined0 undefined-5.03 undefined
2025e0.4 undefined0 undefined-5.17 undefined
2024e0.23 undefined0 undefined-6.11 undefined
20231.73 undefined-15.88 undefined-12.66 undefined
20220.33 undefined-4.96 undefined-4.81 undefined
20210.31 undefined-4.89 undefined-4.68 undefined
20201.29 undefined-10.16 undefined-9.67 undefined
20193.59 undefined-8.17 undefined-7.26 undefined
20185.95 undefined-10.3 undefined-10.11 undefined
201713.24 undefined-18.51 undefined-17.44 undefined
201645.43 undefined-24.83 undefined-14.13 undefined
201551.59 undefined-41.82 undefined-46.06 undefined
201450.29 undefined-76.86 undefined-47.93 undefined
201332.2 undefined-71.6 undefined-100.6 undefined
201244.86 undefined-67 undefined-59.43 undefined
2011109.43 undefined-42.29 undefined-34 undefined
201027.86 undefined-112.57 undefined-105.57 undefined
200947 undefined-100.83 undefined-100.5 undefined
200877 undefined-115.33 undefined-114 undefined
200742 undefined-211 undefined-205.33 undefined
2006115.5 undefined-320 undefined-408 undefined
2005154 undefined-234 undefined-236 undefined
2004100 undefined-592 undefined-638 undefined

Soligenix business model

Soligenix Inc. is a biopharmaceutical company specialized in the development of treatment and prevention methods for serious diseases. It was founded in 1987 and is headquartered in Princeton, New Jersey. The business model of Soligenix Inc. is based on the research and development of innovative therapies for diseases that are currently difficult to treat or have no known cure. The company's research and development focus on three core areas: vaccines, cancer therapies, and rare diseases. In the field of vaccines, Soligenix Inc. has focused on developing therapies against biological threats such as anthrax, smallpox, or botulinum toxin-like toxins. These threats are not only a potential danger to national security but can also occur in the form of natural disasters or terrorist attacks. Soligenix Inc. has several promising vaccine candidates in clinical trials, including an anthrax vaccine that works faster and safer than currently available vaccines. In the field of cancer therapy, the company focuses on developing new immunotherapies for the treatment of solid tumors. Soligenix Inc. uses a technology platform called "RiVax" based on the inactivation of botulinum toxin. This platform has already proven promising in redirecting the body's immune system to tumor cells and killing them. As the last core area, the company is dedicated to the treatment of rare diseases that are often overlooked and insufficiently treated. Soligenix Inc. has already developed a promising candidate for the treatment of oropharyngeal candidiasis (fungal infections in the mouth and throat) and is in phase III clinical trials. Overall, Soligenix Inc. has developed a range of promising products in various stages of clinical trials. In addition to the mentioned candidates, the company has also developed a promising treatment for relieving the side effects of cancer chemotherapy. This product called SGX942 is currently in phase III clinical trials. In addition to ongoing clinical studies, Soligenix Inc. has also established strong partnerships with government organizations such as the US National Institutes of Health or the Biomedical Advanced Research and Development Authority (BARDA). These partnerships are important to secure funding for ongoing research projects and allow the company to bring its products to market quickly. Soligenix Inc. has experienced strong growth in recent years and has established itself as a key player in the biopharmaceutical industry. The company has received several awards for its research work and innovation potential in the past and seems to be on a good path to bring further groundbreaking therapies to the market. Soligenix is one of the most popular companies on Eulerpool.com.

Soligenix SWOT Analysis

Strengths

Soligenix Inc has several key strengths that contribute to its success in the market:

  • Strong and experienced management team
  • Robust portfolio of innovative products and technologies
  • Strong financial position and steady revenue growth
  • Broad and diverse customer base
  • Well-established reputation and brand image

Weaknesses

Despite its strengths, Soligenix Inc also faces certain weaknesses that may hinder its growth:

  • Dependency on a limited number of key suppliers
  • Relatively small market share compared to competitors
  • Higher production costs as a result of specialized manufacturing processes
  • Limited geographical presence and market reach
  • Dependence on regulatory approvals for product development and commercialization

Opportunities

Soligenix Inc has several opportunities that can be capitalized on to drive future growth:

  • Increasing demand for its specialized pharmaceutical products
  • Expansion into new geographic markets
  • Collaboration with strategic partners for joint research and development
  • Emerging trends and regulations favoring the company's product portfolio
  • Growing investments in healthcare infrastructure globally

Threats

Soligenix Inc faces certain threats that may affect its market position and profitability:

  • Intense competition from larger pharmaceutical companies
  • Stringent regulatory requirements and potential delays in product approvals
  • Economic downturns impacting customer spending and market demand
  • Challenges related to intellectual property rights and patent protection
  • Rapidly evolving industry and technological advancements

Soligenix Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Soligenix historical P/E ratio, EBIT multiple, and P/S ratio

Soligenix shares outstanding

The number of shares was Soligenix in 2023 — This indicates how many shares 484,880 is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Soligenix earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Soligenix's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Soligenix’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Soligenix's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Soligenix stock splits

In Soligenix's history, there have been no stock splits.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Soligenix.

Soligenix latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-1.81 -1.31  (27.64 %)2024 Q2
3/31/2024-3.1 -2.88  (7.12 %)2024 Q1
12/31/2023-3.18 -3.68  (-15.64 %)2023 Q4
9/30/2023-4.73 -2.56  (45.91 %)2023 Q3
6/30/2023-8 -3.52  (55.98 %)2023 Q2
3/31/2023-20.4 -5.76  (71.76 %)2023 Q1
12/31/2022-18.36 -73.28  (-299.13 %)2022 Q4
9/30/2022-22.03 -19.2  (12.85 %)2022 Q3
6/30/2022-19.58 -14.4  (26.47 %)2022 Q2
3/31/2022-17.14 -24  (-40.06 %)2022 Q1
1
2
3
4
5
...
6

Soligenix shareholders

%
Name
Stocks
Change
Date
3.50877 % Armistice Capital LLC80,00080,0006/30/2024
2.02904 % Stephens Capital Management46,26246,2629/30/2024
0.27329 % UBS Financial Services, Inc.6,2316,1426/30/2024
0.16105 % Tower Research Capital LLC3,6723,2376/30/2024
0.01662 % Schaber (Christopher J)37937/19/2024
0.01316 % Plante Moran Financial Advisors, LLC30016/30/2024
0.00978 % Morgan Stanley & Co. LLC223-16/30/2024
0.00421 % Zeldis (Jerome B)9607/19/2024
0.00276 % Parks (Diane L.)6317/19/2024
0.00202 % Guarino (Jonathan L.)4607/19/2024
1
2
3
4
5
...
6

Soligenix Executives and Management Board

Dr. Christopher Schaber(56)
Soligenix Chairman of the Board, Chief Executive Officer and President (since 2006)
Compensation 711,186
Dr. Oreola Donini(51)
Soligenix Senior Vice President, Chief Scientific Officer
Compensation 364,242
Mr. Jonathan Guarino(51)
Soligenix Chief Financial Officer, Senior Vice President, Corporate Secretary
Compensation 355,350
Dr. Richard Straube(71)
Soligenix Senior Vice President and Chief Medical Officer
Compensation 242,334
Mr. Gregg Lapointe(64)
Soligenix Independent Director
Compensation 87,500
1
2

Soligenix Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Emergent BioSolutions Stock
Emergent BioSolutions
SupplierCustomer0,910,860,930,630,780,87
Boston Scientific Stock
Boston Scientific
SupplierCustomer0,070,520,740,400,37-0,71
1

Most common questions regarding Soligenix

What values and corporate philosophy does Soligenix represent?

Soligenix Inc represents values of innovation, integrity, and commitment to improving healthcare. The company's corporate philosophy revolves around developing and commercializing innovative therapeutics for unmet medical needs, particularly in the areas of oncology, rare diseases, and inflammation. Soligenix Inc strives to provide cutting-edge solutions to improve patient outcomes and enhance quality of life. With a strong focus on research and development, Soligenix Inc aims to create effective and safe therapies that address significant medical challenges. As a healthcare-focused company, Soligenix Inc is dedicated to promoting advancements in medical science and making a positive impact on global health.

In which countries and regions is Soligenix primarily present?

Soligenix Inc is primarily present in the United States.

What significant milestones has the company Soligenix achieved?

Some significant milestones achieved by Soligenix Inc include the successful completion of Phase 3 clinical trials for SGX301, its lead product candidate for the treatment of cutaneous T-cell lymphoma. The company also received two Fast Track designations from the U.S. FDA for SGX301, which highlights its potential to address unmet medical needs. Soligenix Inc has demonstrated positive results in multiple clinical studies, optimizing its drug delivery platforms and enhancing their commercialization potential. Furthermore, the company has made advancements in the development of innate defense regulator (IDR) technology, presenting promising results in various indications. Throughout its history, Soligenix Inc has continuously focused on advancing innovative therapies for unmet medical needs, making significant progress and positioning itself as a leader in biopharmaceutical research and development.

What is the history and background of the company Soligenix?

Soligenix Inc is a biopharmaceutical company specializing in developing and commercializing healthcare products. Founded in 1987, Soligenix Inc has a strong history of innovation and a commitment to improving patient outcomes. The company focuses on areas such as oncology, gastrointestinal diseases, and biodefense. Soligenix Inc has a broad portfolio of products in various stages of development, including advancements in cancer treatments and vaccines. With a dedicated team of experienced professionals and a reputation for excellence, Soligenix Inc continues to drive advancements in healthcare by delivering effective and life-changing therapies to patients worldwide.

Who are the main competitors of Soligenix in the market?

The main competitors of Soligenix Inc in the market are pharmaceutical companies that operate in the same product and therapeutic areas. Soligenix Inc faces competition from industry leaders such as Amgen, Pfizer, and Novartis. These companies have similar offerings and target the same patient populations. However, Soligenix Inc differentiate themselves through their unique product pipeline and focus on developing innovative therapies. While competition remains intense, Soligenix Inc continues to strive for excellence and deliver value to its stakeholders.

In which industries is Soligenix primarily active?

Soligenix Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Soligenix?

Soligenix Inc operates as a biopharmaceutical company. The company is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Soligenix Inc primarily focuses on two therapeutic areas: oncology and inflammatory diseases. The company's business model revolves around conducting research, clinical development, and seeking regulatory approvals for its drug candidates. Soligenix Inc aims to bring innovative treatments to market, addressing the needs of patients suffering from rare diseases.

What is the P/E ratio of Soligenix 2024?

The Soligenix P/E ratio is -0.12.

What is the P/S ratio of Soligenix 2024?

The Soligenix P/S ratio is 3.27.

What is the Quality Investing of Soligenix?

The Quality Investing for Soligenix is 2/10.

What is the revenue of Soligenix 2024?

The expected Soligenix revenue is 519,690 USD.

How high is the profit of Soligenix 2024?

The expected Soligenix profit is -13.94 M USD.

What is the business model of Soligenix

Soligenix Inc is a biopharmaceutical company specialized in the development and commercialization of therapeutics. The company has a wide product pipeline focused on three key areas: biodefense, orphan and rare diseases, and cancer. Soligenix has a successful track record in developing therapeutics based on technologies such as Controlled Release, Dendrimer technology, among others. The company has recently made several important advances in the development of new therapy options, including a collaborative impregnation licensing agreement with Nemaura Medical. The biodefense division of Soligenix aims to develop products and technologies that help reduce the impact of infections and diseases from biological threats. The company has three main products in this area: RiVax(TM), a vaccine against Rickettsia prowazekii to protect against typhus; CoVaccine HT(TM), a vaccine adjuvant used to improve immune response; SGX943 (still in preclinical phase), an anti-inflammatory agent for acute radiation injuries aiming to improve survival and recovery in nuclear accidents or other harmful radiation events. Soligenix focuses on developing therapies for orphan and rare diseases supported by legislation to treat rare diseases with no approved therapies. The company has a broad range of products in this area, some of the most advanced being: SGX301, a topical photodynamic therapy for the treatment of cutaneous T-cell lymphomas; SGX942, a treatment option for preventing and treating mucositis in cancer patients responding to chemotherapy; SGX203, the first and only oral system targeting the ferritin receptor effective in treating anemia in patients with chronic kidney disease. In the cancer division, Soligenix has launched several important projects for the development of treatment options for cancer patients. Some of the key products in this area include: SGX301, which can be used as a means of treating cancer cells associated with various types of cancer; SGX943, an anti-inflammatory drug aiming to support the body in recovering from the negative effects of radiation therapy in cancer treatments. All products share the goal of providing innovative solutions to improve people's lives and their chances of survival. Thanks to close collaboration with leading research institutions and organizations worldwide, Soligenix is well positioned to achieve a leading position in the biopharmaceutical industry.

What is the Soligenix dividend?

Soligenix pays a dividend of 0 USD distributed over payouts per year.

How often does Soligenix pay dividends?

The dividend cannot currently be calculated for Soligenix or the company does not pay out a dividend.

What is the Soligenix ISIN?

The ISIN of Soligenix is US8342233074.

What is the Soligenix WKN?

The WKN of Soligenix is A2AS7Q.

What is the Soligenix ticker?

The ticker of Soligenix is SNGX.

How much dividend does Soligenix pay?

Over the past 12 months, Soligenix paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Soligenix is expected to pay a dividend of 0 USD.

What is the dividend yield of Soligenix?

The current dividend yield of Soligenix is .

When does Soligenix pay dividends?

Soligenix pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Soligenix?

Soligenix paid dividends every year for the past 0 years.

What is the dividend of Soligenix?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Soligenix located?

Soligenix is assigned to the 'Health' sector.

Wann musste ich die Aktien von Soligenix kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Soligenix from 11/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/9/2024.

When did Soligenix pay the last dividend?

The last dividend was paid out on 11/9/2024.

What was the dividend of Soligenix in the year 2023?

In the year 2023, Soligenix distributed 0 USD as dividends.

In which currency does Soligenix pay out the dividend?

The dividends of Soligenix are distributed in USD.

All fundamentals about Soligenix

Our stock analysis for Soligenix Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Soligenix Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.